Silas Inman

Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.

Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com

Articles

ODAC Unanimously Supports Axitinib for Renal Cell Carcinoma

December 8th 2011

ODAC unanimously voted to recommend the approval of axitinib for the second-line treatment of patients with advanced renal cell carcinoma.

FDA Grants Orphan Drug Status to Erwinaze for Treatment of Acute Lymphoblastic Leukemia

November 18th 2011

The FDA granted orphan drug approval to Erwinaze (asparaginase Erwinia chrysanthemi) to treat acute lymphoblastic leukemia (ALL).

Vemurafenib Receives Approval for Metastatic Melanoma

August 17th 2011

The FDA approved vemurafenib and a companion diagnostic test in a move that was hailed as an advance for both patients and personalized medicine.

Erlotinib Extends PFS in EGFR-Positive Lung Cancer

July 25th 2011

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

FDA Panel Unanimously Supports New Lymphoma Treatment

July 15th 2011

ODAC unanimously recommended accelerated approval for brentuximab vedotin (Adcetris) in 2 types of lymphoma.

Amgen Seeks to Expand Xgeva's FDA Approval

July 11th 2011

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasisâ€“free survival with Xgeva versus placebo.

NCI Examines Cediranib to Fight Metastatic Prostate Cancer

July 7th 2011

Prostate cancer metastases, or cancer growing outside the prostate glands, can occur in any organ but is seen most frequently in the bone.

Celecoxib: Effective in Former Smokers as Lung Cancer Chemoprevention

July 6th 2011

A recent study revealed that celecoxib (Celebrex), a COX-2 inhibitor, might be a successful lung cancer chemoprevention in former smokers.

New Genetic Test Aids Detection of HER2+ Breast Cancer

June 15th 2011

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer